MetaVia (NASDAQ:MTVA) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of MetaVia (NASDAQ:MTVA) from a sell rating to a hold rating in a research report report published on Saturday.

Several other analysts have also recently issued reports on MTVA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MetaVia in a research report on Monday, December 22nd. HC Wainwright upped their price objective on MetaVia from $12.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, MetaVia currently has a consensus rating of “Hold” and an average price target of $36.50.

MetaVia Stock Performance

NASDAQ MTVA opened at $3.11 on Friday. MetaVia has a one year low of $2.95 and a one year high of $23.54. The company has a market capitalization of $6.84 million, a price-to-earnings ratio of -0.37 and a beta of 0.27. The company’s 50-day simple moving average is $8.19 and its two-hundred day simple moving average is $8.68.

MetaVia (NASDAQ:MTVA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($1.54) earnings per share for the quarter, topping the consensus estimate of ($2.86) by $1.32. Equities analysts expect that MetaVia will post -3.9 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in MetaVia stock. SG Americas Securities LLC raised its holdings in MetaVia Inc. (NASDAQ:MTVA) by 44.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 60,386 shares of the company’s stock after buying an additional 18,506 shares during the quarter. SG Americas Securities LLC owned about 0.25% of MetaVia worth $57,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.37% of the company’s stock.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.